世界の統合失調症治療薬市場の規模は2023年に79億ドルと評価され、2024年から2030年にかけて5.3%のCAGRで成長すると予測されます。需要が増加する要因は、統合失調症やその他の関連するメンタルヘルス障害の有病率が世界中で高まっていることにあります。この増加は、遺伝的、環境的、および社会経済的要因に起因する可能性があります。認知度と診断が向上するにつれて、より多くの個人が統合失調症と特定され、その結果、効果的な治療オプションの需要が高まっています。
目次
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Schizophrenia Drugs Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Schizophrenia Drugs Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Schizophrenia Drugs Market: Class Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Schizophrenia Drugs Market: Class Movement Analysis, 2023 & 2030 (USD Million)
4.2.1. Second-Generation Antipsychotics
4.2.1.1. Second-Generation Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.2. Risperdal (Risperidone)
4.2.1.2.1. Risperdal (Risperidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.3. Invega (Paliperidone)
4.2.1.3.1. Invega (Paliperidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.4. Zyprexa (Olanzapine)
4.2.1.4.1. Zyprexa (Olanzapine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.5. Geodon (Ziprasidone)
4.2.1.5.1. Geodon (Ziprasidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.6. Seroquel (Quetiapine)
4.2.1.6.1. Seroquel (Quetiapine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.7. Latuda (Lurasidone)
4.2.1.7.1. Latuda (Lurasidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.8. Aristada (Aripiprazole Lauroxil)
4.2.1.8.1. Aristada (Aripiprazole Lauroxil) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.9. Fanapt (Iloperidone)
4.2.1.9.1. Fanapt (Iloperidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.10. Saphris (Asenapine)
4.2.1.10.1. Saphris (Asenapine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.11. Vraylar (Cariprazine)
4.2.1.11.1. Vraylar (Cariprazine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2. Third-Generation Antipsychotics
4.2.2.1. Third-Generation Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.2. Abilify (Aripiprazole)
4.2.2.2.1. Abilify (Aripiprazole) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3. Others
4.3.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2. First-Generation Antipsychotics
4.3.2.1. First-Generation Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.3. Generics
4.3.3.1. Generics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Schizophrenia Drugs Market: Treatment Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Schizophrenia Drugs Market: Treatment Movement Analysis, 2023 & 2030 (USD Million)
5.2.1. Oral Antipsychotics
5.2.1.1. Oral Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.2. Injectable Antipsychotics
5.2.2.1. Injectable Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Schizophrenia Drugs Market: Distribution Channel Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Schizophrenia Drugs Market: Distribution channel Movement Analysis, 2023 & 2030 (USD Million)
6.2.1. Hospital Pharmacies
6.2.1.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.2. Retail Pharmacies
6.2.2.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.3. Online Pharmacies
6.2.3.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.4. Others
6.2.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Schizophrenia Drugs Market: Regional Estimates & Trend Analysis
7.1. Schizophrenia Drugs Market Share, By Region, 2023 & 2030 (USD Million)
7.2. North America
7.2.1. North America Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. U.K.
7.3.2.1. U.K. Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Italy Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Spain Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Denmark Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Sweden Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Norway Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. China
7.4.2.1. China Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Japan Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. South Korea Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Australia Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Thailand Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. Saudi Arabia
7.6.2.1. Saudi Arabia Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. UAE
7.6.3.1. UAE Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. South Africa
7.6.4.1. South Africa Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. Johnson & Johnson
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Bristol-Myers Squibb/ Otsuka Pharma
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. AstraZeneca
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Sumitomo Dainippon
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Eli Lilly & Company
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. Alkermes
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Vanda Pharma
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Allergan
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. Pfizer
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
8.4.10. H. Lundbeck A/S
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/ Strategic Initiatives
